Výsledky vyhledávání

Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma

Autor: U. Harnest, José Luis Izquierdo, P. Hofbauer, K.-D. Rost, B. Kroemer, M. Aubier, L. M. Adler, Dirk Bredenbröker, A. Albrecht, Jean Bousquet, Joaquín Sastre

Publikováno v: Allergy. 61:72-78

Background: Roflumilast is an oral, once-daily phosphodiesterase 4 inhibitor with anti-inflammatory activity in development for the treatment of asthma. Roflumilast was compared with inhaled beclomethasone dipropionate (BDP) in patients with asthma.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86248199d1a4609a170928c2fb1ad8fa
https://doi.org/10.1111/j.1398-9995.2005.00931.x

Zobrazit plný text záznamu

Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma

Autor: J, Bousquet, M, Aubier, J, Sastre, J L, Izquierdo, L M, Adler, P, Hofbauer, K-D, Rost, U, Harnest, B, Kroemer, A, Albrecht, D, Bredenbröker

Publikováno v: Allergy. 61(1)

Roflumilast is an oral, once-daily phosphodiesterase 4 inhibitor with anti-inflammatory activity in development for the treatment of asthma. Roflumilast was compared with inhaled beclomethasone dipropionate (BDP) in patients with asthma.In a double b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a169a32841f0f17ffe1c735bf9929a87
https://pubmed.ncbi.nlm.nih.gov/16364159

Zobrazit plný text záznamu

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler

Autor: Barry N. Lutsky, R Suárez-Chacón, U Harnest, Jacques Hébert, Jean Bousquet, Bo Lundbäck, G Martinez Morales, S Visser, M M Nieminen, C H Barraza, Anthony D'Urzo, K.B. Nolop, L.-P. Boulet

Publikováno v: The European respiratory journal. 16(5)

Mometasone furoate (MF) administered by dry powder inhaler (DPI) was composed with budesonide (BUD) Turbuhaler in the treatment of moderate persistent asthma. The patients were randomized to one of four treatment groups: MF DPI (100, 200, 400 microg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93ea4e55caa25b4b9f36bdd16596ba3c
https://pubmed.ncbi.nlm.nih.gov/11491182

Zobrazit plný text záznamu

[Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma]

Autor: U. Harnest, R. Sakalauskas, N. Vetter, V. W. Steinijans, H. Steffen, Asaf Keller, S. Leichtl, F. Rathgeb, P. Magyar, D. Ukena

Publikováno v: Pneumologie (Stuttgart, Germany). 52(7)

The anti-asthmatic effects of theophylline may supplement those of inhaled steroids in asthma. The aim of the present trial was to study how the addition of theophylline compares to doubling the dose of inhaled steroid in asthmatics who remain sympto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6150462e2b43baa1cbedec2a5d8f88fa
https://pubmed.ncbi.nlm.nih.gov/9738387

Zobrazit plný text záznamu

Omalizumab, an anti-IgE antibody, improves both asthma- and rhinitis-related quality of life in patients with concomitant moderate-severe disease*1

Autor: M. Blogg, Howard Fox, U. Harnest, S. Hedgecock, L.-P. Boulet, K. Surrey

Publikováno v: Journal of Allergy and Clinical Immunology. 113:S176

Rationale Patients with allergic asthma (AA) frequently experience concomitant persistent allergic rhinitis (PAR). Omalizumab, a humanized monoclonal anti-IgE antibody, improves quality of life (QoL) in patients with AA or PAR. This is the first stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25c472fb4a9b84d16bc41ebf2ddd1d58
https://doi.org/10.1016/j.jaci.2004.01.067

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Effectiveness and tolerance of the C3 convertase inhibitor, N-acetyl-aspartyl-magnesium glutamate in perennial rhinitis. Results of a double-blind, placebo-controlled study]

Autor: U, Harnest, R, Kiehn, C, Sieger, M A, Weibel

Publikováno v: Arzneimittel-Forschung. 39(2)

N-Acetyl-aspartyl magnesium glutamate (Rhinaaxia, NAAGA) is a new antiallergic substance for topical use. The compound covers a bilateral way of action. There is inhibition of the mast cell-degranulation and blocking of the C3-convertase, subsequentl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e4e3424eeaa7d78a60afd5253f238ce8
https://pubmed.ncbi.nlm.nih.gov/2659003

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání